This week’s round of insights focuses on three recent hot topics in the healthcare industry.
Should we worry about a hantavirus outbreak?
A hantavirus outbreak linked to a cruise ship has recently raised concerns around infectious disease surveillance and outbreak containment in travel settings. According to reports from the World Health Organization (WHO), several passengers developed symptoms consistent with Andes hantavirus (ANDV) infection after exposure during the voyage.
Hantaviruses are primarily spread through contact with infected rodent urine, droppings or saliva and can cause severe respiratory symptoms. The incident has prompted strict onboard sanitation measures, and international coordination between health authorities.
WHO experts noted that global travel environments such as cruise ships can complicate outbreak management due to close, prolonged contact between passengers from multiple countries. However, according to the WHO, the global public health risk is low and routine travel remains safe, as there is no evidence of community spread.
Exercise can lower mortality risk in CKD
New research from Renal Failure has suggested that regular physical activity may significantly reduce mortality risk in patients with chronic kidney disease (CKD).
The study found that exercise lowered all-cause and cardiovascular mortality, thus reaffirming exercise as an important part of CKD management. CKD is associated with increased cardiovascular risk, reduced physical function, and poor quality of life.
Researchers noted that even moderate activity levels appeared beneficial and supported recommendations for integrating physical activity into routine patient care where appropriate.
FDA approves Breztri for young asthma patients
The FDA has approved AstraZeneca’s Breztri Aerosphere for the treatment of asthma in patients aged 12 years and older. This approval expands the drug’s previous indication in chronic obstructive pulmonary disease (COPD).
The inhaled therapy combines budesonide, glycopyrrolate and formoterol fumarate to target airway inflammation and bronchoconstriction. The approval was supported by clinical trial data showing improvements in lung function and asthma control.
The decision also reflects the FDA’s goal to move toward combination inhaler approaches to simplify treatment regimens and improve adherence.
For more industry insights visit elion.nz/insights/
Want to get in touch? Contact us today at https://elion.nz/get-in-touch/
